We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-2.38%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.86B
AUM Growth
-$456M
Cap. Flow
-$272M
Cap. Flow %
-14.61%
Top 10 Hldgs %
79.17%
Holding
33
New
4
Increased
4
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$54M
2
MYOV
Myovant Sciences Ltd.
MYOV
+$44.8M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$40M
4
STOK icon
Stoke Therapeutics
STOK
+$30.1M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$14.6M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$106M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$70.5M
3
SAGE
Sage Therapeutics
SAGE
+$61.1M
4
KALV
KalVista Pharmaceuticals
KALV
+$41.2M
5
AXSM icon
Axsome Therapeutics
AXSM
+$39.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$476M 25.54%
4,132,442
– –
WVE icon
2
Wave Life Sciences
WVE
$1.11B
$203M 10.89%
7,775,207
– –
ZGNX
3
DELISTED
Zogenix, Inc.
ZGNX
$178M 9.55%
3,722,504
+1,340,336
+56% +$54M
RARX
4
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$137M 7.35%
4,858,260
– –
THOR
5
DELISTED
Synthorx, Inc. Common Stock
THOR
$131M 7.05%
9,724,598
– –
EIDX
6
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$113M 6.05%
2,162,671
– –
ORTX
7
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$71.5M 3.84%
510,833
– –
TGTX icon
8
TG Therapeutics
TGTX
$8.28B
$59.5M 3.19%
6,880,323
-1,318,014
-16% -$9.96M
MYOV
9
DELISTED
Myovant Sciences Ltd.
MYOV
$59.2M 3.18%
6,545,642
+3,001,415
+85% +$44.8M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.88B
$46.9M 2.52%
1,875,209
– –
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$7.39B
$41.5M 2.23%
1,884,782
– –
DRNA
12
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$38.7M 2.08%
2,456,669
– –
ARVN icon
13
Arvinas
ARVN
$531M
$37.1M 1.99%
1,688,412
-450,000
-21% -$9.46M
PRVL
14
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$36.2M 1.94%
+2,743,625
New +$40M
AXSM icon
15
Axsome Therapeutics
AXSM
$11.8B
$34.5M 1.85%
1,340,828
-1,952,961
-59% -$39.1M
STOK icon
16
Stoke Therapeutics
STOK
$1.81B
$32.7M 1.75%
+1,119,963
New +$30.1M
KALA icon
17
KALA BIO
KALA
$12.2M
$28.9M 1.55%
1,817
– –
SWAV
18
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$28.3M 1.52%
495,608
– –
DTIL icon
19
Precision BioSciences
DTIL
$176M
$24.4M 1.31%
61,412
– –
SLDB icon
20
Solid Biosciences
SLDB
$802M
$21.3M 1.14%
179,296
– –
ALEC icon
21
Alector
ALEC
$171M
$19M 1.02%
1,000,000
– –
GTHX
22
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$14.8M 0.8%
483,990
+120,939
+33% +$2.55M
XFOR icon
23
X4 Pharmaceuticals
XFOR
$377M
$12.9M 0.69%
+28,713
New +$14.6M
SCPH
24
DELISTED
scPharmaceuticals
SCPH
$10.4M 0.56%
3,247,005
+389,862
+14% +$1.28M
ODT
25
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$7.34M 0.39%
+200,000
New +$4.79M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, RA Capital Management held 33 positions worth $1.86B, down 20% from $2.32B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

RA Capital Management withdrew a net $272M in Q2 2019, closing 8 positions and reducing 3 holdings. Its most notable exit was InflaRx, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Prevail Therapeutics Inc. Common Stock worth $36.2M.

  • RA Capital Management's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 2,743,625 shares worth $36.2M.
  • RA Capital Management added most to Zogenix, Inc. in Q2 2019, an estimated $54M increase.
  • RA Capital Management's biggest Q2 2019 reduction was Axsome Therapeutics, cutting an estimated $39.1M.
  • RA Capital Management fully exited InflaRx in Q2 2019, selling an estimated $106M.
  • RA Capital Management's ten largest holdings make up 79% of its $1.86B portfolio in Q2 2019.
  • RA Capital Management opened 4 new positions and closed 8 in Q2 2019.
  • RA Capital Management's portfolio value fell 20% quarter-over-quarter to $1.86B.

Based on RA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.